NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free TVGN Stock Alerts $0.81 +0.03 (+3.86%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.76▼$0.8150-Day Range$0.77▼$3.9752-Week Range$0.75▼$21.09Volume119,032 shsAverage Volume1.50 million shsMarket Capitalization$12.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrends Get Tevogen Bio alerts: Email Address Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Tevogen Bio Stock (NASDAQ:TVGN)Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.Read More TVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVGN Stock News HeadlinesMay 30 at 8:15 PM | investorplace.comTVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024May 29 at 4:09 PM | finanznachrichten.deTevogen Bio Inc: Tevogen Bio Reports First Quarter 2024 Financial ResultsMay 29 at 8:00 AM | globenewswire.comTevogen Bio Reports First Quarter 2024 Financial ResultsMay 17, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic InitiativesMay 16, 2024 | globenewswire.comTevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic InitiativesMay 13, 2024 | msn.comWhy Is Tevogen Bio (TVGN) Stock Up 54% Today?May 13, 2024 | investorplace.comWhy Is Tevogen Bio (TVGN) Stock Up 54% Today?May 11, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational ObjectivesMay 10, 2024 | globenewswire.comTevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational ObjectivesMay 1, 2024 | globenewswire.comTevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational ObjectivesApril 27, 2024 | finanznachrichten.deTevogen Bio Inc: Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership AppointmentsApril 26, 2024 | globenewswire.comTevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership AppointmentsApril 26, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.98%April 20, 2024 | morningstar.comTevogen Bio Holdings Inc TVGNApril 16, 2024 | msn.comLive Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionApril 11, 2024 | finance.yahoo.comTevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target CancersApril 11, 2024 | globenewswire.comTevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target CancersApril 5, 2024 | seekingalpha.comTVGN Tevogen Bio Holdings Inc.April 4, 2024 | investorplace.comWhy Is Tevogen Bio (TVGN) Stock Up 46% Today?April 3, 2024 | globenewswire.comTevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate DevelopmentMarch 28, 2024 | globenewswire.comTevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion PriceMarch 27, 2024 | globenewswire.comTevogen Bio Announces Series A-1 Preferred Stock InvestmentMarch 20, 2024 | businesswire.comTevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 VariantFebruary 27, 2024 | businesswire.comMittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AIFebruary 21, 2024 | businesswire.comCell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID TreatmentSee More Headlines Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CUSIPN/A CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-273.73% Return on Assets229.30% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-1.05Miscellaneous Outstanding Shares15,820,000Free Float6,864,000Market Cap$12.77 million OptionableN/A Beta0.49 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Ryan H. Saadi M.D. (Age 59)M.P.H, M.P.H., Co-Founder, CEO & Chairman Comp: $501kMr. Kirti Desai (Age 67)Chief Financial Officer Comp: $300kDr. Neal Flomenberg M.D. (Age 70)Chief Scientific Officer and Global R&D Lead Comp: $350kMr. Sadiq Khan (Age 62)Chief Commercial Officer Key CompetitorsAligos TherapeuticsNASDAQ:ALGSIN8bioNASDAQ:INABOKYO PharmaNASDAQ:OKYOBrainstorm Cell TherapeuticsNASDAQ:BCLIAchilles TherapeuticsNASDAQ:ACHLView All CompetitorsInstitutional OwnershipPortland Global Advisors LLCBought 5,782,209 shares on 5/9/2024Ownership: 36.550%View All Institutional Transactions TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed in 2024? Tevogen Bio's stock was trading at $9.51 at the beginning of the year. Since then, TVGN shares have decreased by 91.5% and is now trading at $0.8075. View the best growth stocks for 2024 here. Who are Tevogen Bio's major shareholders? Tevogen Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Portland Global Advisors LLC (36.55%). How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVGN) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
